<DOC>
	<DOC>NCT00437450</DOC>
	<brief_summary>The purpose of this study is - To evaluate the efficacy of association of Erythropoetin (Neorecormon) and ATRA in patients with low risk myelodysplastic syndromes - To evaluate the tolerance of this treatment</brief_summary>
	<brief_title>Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients ≥18 years with RA, RARS, RAEB (blasts &lt;10%) Hb&lt; 10g/dl &gt; of 2 months or transfused since less 2 months Hb&lt;12g/dl &gt; of 2 months and thrombocytopenia defined by platelets &lt; 50 000/mm3, or neutropenia&lt;10 000mm3 For women of child bearing age, necessity of contraception during all the duration of the study Patient with lung disease, cardiac, neurological, gastrointestinal or genito urinary disorders not connected to genito urinary not connected to myelodysplasia Patient having received intensive chemotherapy in the 3 months before inclusion in the protocol RAEBt RAEB &gt;10% blasts Treatment with rHuEpo, darbepoetin ou rHuGCSF , 2 months before inclusion Patient presenting an iron , B12 vitamin or folic acid uncorrected deficit CMML Uncontrolled systemic hypertension creatinine clearance &lt; 300 µM/L Pregnant patient or in period of lactation Life expectancy &lt; 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Anemia</keyword>
	<keyword>myelodysplastic syndromes</keyword>
	<keyword>Low risk</keyword>
	<keyword>Bone Marrow diseases</keyword>
</DOC>